Notably, patients with positive PD-L1 status exhibited a more favorable hazard ratio and in a subgroup analysis, patients with a PD-L1 expression level of less than 1% in tumor cells did not experience a significant therapeutic benefit (5). The gene discussed is CD274; the disease is neoplasm.